Pfizer Interested In Commercializing Gamida Cell’s Cancer Treatment

Pharmaceutical giant Pfizer is in contact with Israeli companies Gamida Cell and TEVA, with intent of commercializing Gamida Cell’s StemEX, a treatments for lymphoma and leukemia (which is partially owned by TEVA). Israeli economics magazine Calcalist reports that if the deal goes through, Gamida cell will receive tens of millions of dollars in advance plus grants for milestones reached. Gamida Cell specializes in developing stem cell therapy projects.